IP
RLAY icon

Intellectus Partners’s Relay Therapeutics RLAY Stock Holding History

Intellectus Partners’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Sell
20,225
-22,000
-52% -$319K 0.07% 229
2026
Q1 		$420K Sell
42,225
-1,700
-4% -$15.2K 0.09% 222
2025
Q4 		$372K Sell
43,925
-12,500
-22% -$89.2K 0.07% 212
2025
Q3 		$295K Sell
56,425
-5,000
-8% -$19.1K 0.06% 237
2025
Q2 		$213K Hold
61,425
– – 0.05% 259
2025
Q1 		$161K Hold
61,425
– – 0.04% 256
2024
Q4 		$253K Sell
61,425
-6,250
-9% -$34K 0.06% 238
2024
Q3 		$479K Hold
67,675
– – 0.12% 187
2024
Q2 		$441K Sell
67,675
-1,585
-2% -$10.8K 0.12% 181
2024
Q1 		$575K Buy
69,260
+19,400
+39% +$189K 0.15% 174
2023
Q4 		$549K Sell
49,860
-700
-1% -$5.91K 0.16% 167
2023
Q3 		$425K Buy
50,560
+2,000
+4% +$21.5K 0.13% 187
2023
Q2 		$610K Buy
48,560
+21,675
+81% +$270K 0.18% 159
2023
Q1 		$443K Sell
26,885
-1,900
-7% -$34.1K 0.14% 180
2022
Q4 		$430K Buy
28,785
+2,800
+11% +$53.6K 0.15% 175
2022
Q3 		$581K Buy
25,985
+1,725
+7% +$37.9K 0.21% 133
2022
Q2 		$406K Buy
24,260
+1,790
+8% +$38.4K 0.14% 181
2022
Q1 		$673K Sell
22,470
-3,700
-14% -$89.8K 0.2% 130
2021
Q4 		$804K Sell
26,170
-8,024
-23% -$254K 0.2% 131
2021
Q3 		$1.08M Buy
34,194
+150
+0.4% +$5.05K 0.26% 104
2021
Q2 		$1.25M Buy
34,044
+9,189
+37% +$303K 0.28% 93
2021
Q1 		$859K Buy
24,855
+15,105
+155% +$656K 0.24% 129
2020
Q4 		$405K Buy
+9,750
New +$441K 0.12% 175

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Intellectus Partners's RLAY Position: Q2 2026 in Review

Intellectus Partners reduced its Relay Therapeutics (RLAY) stake by 52% in Q2 2026, selling an estimated $319K and leaving 20,225 shares worth $378K. The position accounts for 0.07% of the portfolio, ranked #229.

Intellectus Partners first reported a position in RLAY in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.25M in Q2 2021. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Intellectus Partners held 20,225 shares of Relay Therapeutics worth $378K as of Q2 2026.
  • Intellectus Partners sold 22,000 Relay Therapeutics shares in Q2 2026, an estimated $319K.
  • Relay Therapeutics made up 0.07% of Intellectus Partners's portfolio in Q2 2026, its #229 holding.
  • Intellectus Partners first reported a position in Relay Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Intellectus Partners's Relay Therapeutics position peaked at $1.25M in Q2 2021.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Intellectus Partners's 13F filing for Q2 2026, filed 12 Aug 2026.